Recombinant LH
Phase 2Small molecule
Recombinant LH is one of 59 small molecule programs targeting Ovarian Reserve. It is currently in Phase 2.
2
Indications
4
Total Trials
1
Active Trials
58
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
177 competitors in Obesity
#DrugCompanyPhaseTrials
1Cagrilintide
Novo NordiskPhase 3
Decadron
AAspen Global Incorporated
Phase 3
Revlimid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Enavogliflozin
Daewoong Pharmaceutical Co. LTD.Phase 3
Retatrutide
Eli LillyPhase 3
Berobenatide
PfizerPhase 3
HRS9531
FFujian Shengdi Pharmaceutical Co., Ltd.
Phase 3
Naltrexone-Bupropion Combination
CCurrax Pharmaceuticals
Phase 3
Belantamab Mafodotin-Blmf
Novo NordiskPhase 3
Survodutide
Boehringer IngelheimPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Oocyte1 trial
GnRH Antagonist1 trial
Severe LH Suppressed Patients After Administration of a GnRH Antagonist
Completed·—·Phase 4·NCT01936077·50 enrolled
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Recombinant LH. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- UUniversity of Colorado, Denver